NCT04322565View on ClinicalTrials.gov

Colchicine Counteracting Inflammation in COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

April 20, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

October 1, 2021

Conditions
Coronavirus InfectionsPneumonia, Viral
Interventions
DRUG

Colchicine

Cochicine 1mg/day

Trial Locations (1)

43100

Azienda Ospedaliero Universitaria di Parma, Parma

All Listed Sponsors
lead

Azienda Ospedaliero-Universitaria di Parma

OTHER

NCT04322565 - Colchicine Counteracting Inflammation in COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter